Anti-GLA Magnetic Beads-IP Kit Product Components
| Components | Storage |
| Anti-GLA Magnetic Beads1,3 | 2-8℃ for 12 months |
| NP40 Cell Lysis Buffer2 | -20℃ for 12 months |
| 5×TBST（pH7.4） | |
| 1×TBST（pH7.4） | |
| ddH2O | |
| CD166 Positive Cell Lysate | -20℃ for 12 months |
| Alkaline Elution Buffer | 2-8℃ for 12 months |
| Acidity Elution Buffer | 2-8℃ for 12 months |
| Neutralization Buffer | 2-8℃ for 12 months |
[1] The IP KIT contains anti-GLA magnetic Beads (2 mg/mL) in phosphate buffered saline (PBS, pH 7.4) with sodium azide (0.1%).
[2] Using NP-40 cell lysate buffer in the kit is required,otherwise,the magnetic beads may be precipitated.
[3] Shipping: Magnetic Beads kits are shipped at ambient temperature in which magnetic beads are provided in liquid buffer.
Anti-GLA Magnetic Beads-IP Kit Product Description
The Anti-GLA magnetic Beads, conjugated with Anti-GLA antibody, are used for immuneprecipitation (IP) of GLA proteins which expressed in vitro expression systems. For IP, the beads are added to a sample containing GLA proteins to form a bead-protein complex. The complex is removed from the solution manually using a magnetic separator. The bound GLA proteins are dissociated from the magnetic beads using an elution buffer. Anti-GLA Magnetic Beads-IP Kit Antibody Information
Immunogen
Recombinant Human alpha-Galactosidase A / GLA Protein (Catalog#12078-H08H)
Species Reactivity
Human alpha-Galactosidase A /
Source
Polyclonal Human Rabbit IgG
Preparation
Produced in rabbits immunized with purified, recombinant Human alpha-Galactosidase A / GLA (rh alpha-Galactosidase A / GLA; Catalog#12078-H08H; NP_000940.1; Met1-Leu429). alpha-Galactosidase A / GLA specific IgG was purified by Human alpha-Galactosidase A / GLA affinity chromatography.
Applications
Immunoprecipitation (IP), Minimum Protein Purification
Anti-GLA Magnetic Beads Immunoprecipitation (IP) Kit Alternative Names
Anti-GALAALCAM Magnetic Beads-Immunoprecipitatiopn (IP) Kit
GLA Background Information
Alpha-galactosidase A, also known as Alpha-D-galactoside galactohydrolase, Alpha-D-galactosidase A, Melibiase and GLA, is a member of the glycosyl hydrolase 27 family. GLA is used as a long-term enzyme replacement therapy in patients with a confirmed diagnosis of Fabry disease. Defects in GLA are the cause of Fabry disease (FD) which is a rare X-linked sphingolipidosis disease where glycolipid accumulates in many tissues. The disease consists of an inborn error of glycosphingolipid catabolism. FD patients show systemic accumulation of globotriaoslyceramide (Gb3) and related glycosphingolipids in the plasma and cellular lysosomes throughout the body. Clinical recognition in males results from characteristic skin lesions (angiokeratomas) over the lower trunk. Patients may show ocular deposits, febrile episodes, and burning pain in the extremities. Death results from renal failure, cardiac or cerebral complications of hypertension or other vascular disease. Deficiency of GLA leads to the accumulation of glycosphingolipids in the vasculature leading to multiorgan pathology. In addition to well-described microvascular disease, deficiency of GLA is also characterized by premature macrovascular events such as stroke and possibly myocardial infarction.
Full Name
galactosidase, alpha
References
Koide T.et al., 1990, FEBS Lett. 259:353-356. Yang C.-C. et al., 2003, Clin. Genet. 63:205-209. Verovnik F. et al.,2004, Eur. J. Hum. Genet. 12:678-681. Nance C.S. et al., 2006, Arch. Neurol. 63:453-457.
新浪微博
腾讯微博
QQ空间
客服
